COLLABORATIVE DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCollaborative Development and Commercialization Agreement • February 2nd, 2021 • California
This Collaborative Development and Commercialization Agreement (the “Agreement”) is entered into as of 26 October 2020 (the “Effective Date”) by and between Amerimmune LLC, a Virginia limited liability company with a place of business at 11212 Waples Mill Rd, Suite 100, Fairfax, Virginia 22030 (“Amerimmune”), and Histogen, Inc., a Delaware corporation with a place of business at 16745 West Bernardo Drive, Suite 200, San Diego, California 92127 (“Histogen”). Amerimmune and Histogen may each be referred to herein by name or as a “Party”, or, collectively, as the “Parties.”
COLLABORATIVE DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCollaborative Development and Commercialization Agreement • November 3rd, 2021 • Tracon Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
This Collaborative Development and Commercialization Agreement (the “Agreement”) is entered into on October 8, 2021 (the “Effective Date”) between Tracon Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business at 4350 La Jolla Village Drive, Suite 800, San Diego, CA, USA (“Tracon”), Eucure (Beijing) Biopharma Co., Ltd., a company organized and existing under the laws of the People’s Republic of China and having its registered address at 23F, Tower 3, China Central Place, No.77, Jian Guo Road, Chaoyang District, Beijing, China (“Eucure”), and, solely with respect to Section 13.15, Eucure’s controlling Affiliate Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a company organized and existing under the laws of the People’s Republic of China and having its registered address at No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park, 102600 Daxing District, Beijing, China (“Parent”). Eucure and Tracon are sometimes referred to herein individually as a “Pa
COLLABORATIVE DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCollaborative Development and Commercialization Agreement • May 8th, 2017 • Achaogen Inc • Pharmaceutical preparations • Delaware
This Collaborative Development and Commercialization Agreement (“Agreement”) is entered into as of April 26, 2016 (“Effective Date”) by and between Microgenics Corporation (hereinafter “Microgenics”), having its principal place of business at 46500 Kato Road, Fremont, California 94538, and Achaogen Inc. (hereinafter “Achaogen”), having a place of business at 7000 Shoreline Court, #371, South San Francisco, California 94080. Both Microgenics and Achaogen are referred to herein individually as a “Party” and collectively as the “Parties.”
Histogen and Amerimmune Enter into a Collaborative Development and Commercialization Agreement for Emricasan in the Treatment of COVID-19Collaborative Development and Commercialization Agreement • October 27th, 2020
SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced entering into a Collaborative Development and Commercialization Agreement with Amerimmune LLC to jointly develop emricasan, an orally active caspase inhibitor, for the treatment of COVID-19. Additionally, Histogen has received Investigational New Drug (IND) approval from the United States Food and Drug Administration (FDA) to initiate a Phase 1 study of emricasan in mild-COVID-19 patients to assess safety and tolerability. Amerimmune, which will lead the development efforts of emricasan, has selected clinical sites at two major medical centers in the New York City metropolitan area to conduct the study. Amerimmune is pursuing non-dilutive funding in order to support the clinical program and anticipates initiati
Amendment Two (2) to the Collaborative Development and Commercialization AgreementCollaborative Development and Commercialization Agreement • November 8th, 2018 • Achaogen, Inc. • Pharmaceutical preparations
This Amendment 2 (“Amendment”), effective upon the date it is signed by both Parties (“Effective Date”), is by and between Microgenics and Achaogen and issued pursuant to the Collaborative Development and Commercialization Agreement (“Agreement”) dated April 26, 2016 and amended November 29, 2017. The defined terms referenced herein retain their meaning as defined in the Agreement. All amended language in this Amendment has been bolded for ease of reference.
